Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on RVNC. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays restated an “equal weight” rating and set a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Finally, Mizuho dropped their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.96.

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $3.07 on Friday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $9.74. The stock has a market cap of $320.48 million, a P/E ratio of -1.59 and a beta of 0.81. The company has a 50 day simple moving average of $4.38 and a two-hundred day simple moving average of $4.47.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. As a group, equities analysts forecast that Revance Therapeutics will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Several large investors have recently made changes to their positions in RVNC. LMR Partners LLP purchased a new position in Revance Therapeutics during the 3rd quarter valued at approximately $11,648,000. Integral Health Asset Management LLC bought a new position in shares of Revance Therapeutics during the 2nd quarter valued at approximately $1,285,000. Alpine Associates Management Inc. purchased a new position in shares of Revance Therapeutics in the third quarter valued at $21,605,000. Oddo BHF Asset Management Sas bought a new stake in Revance Therapeutics in the third quarter worth $3,763,000. Finally, AQR Capital Management LLC raised its stake in Revance Therapeutics by 567.6% during the second quarter. AQR Capital Management LLC now owns 201,080 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 170,960 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.